← All trials
NCT02929121
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2017
- Primary completion
- Jun 1, 2019
- Completion date
- Sep 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- The Task Force for Global HealthLead sponsor
- The Task Force for Global HealthOverall official - principal investigator
- The Task Force for Global HealthReponsible party - principal investigator
- United States Agency for International DevelopmentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.